Breaking News

Financial Report: Lilly

By Gil Roth | January 30, 2014

Cymbalta expiration begins to weigh down sales

Lilly 4Q13

4Q Revenues: $5.8 billion (-2%)

4Q Earnings: $728 million (-12%)

FY Revenues: $23.1 billion (+2%)

FY Earnings: $4.7 billion (+15%)

Comments: The U.S. patent for Cymbalta expired on Dec. 11, 2013, leading U.S. pharma revenues to fall 6% in 4Q13 to $3.0 billion. Cymbalta revenues dropped 38% in 4Q13 to $883 million, while sales in FY13 rose 2% to $5.1 billion. Zyprexa sales dropped 10% in 4Q13 to $348 million and fell 30% in FY13 to $1.2 billion. Humalog posted 19% growth in 4Q13 to $734 million, while Cialis rose 15% to $588 million during the quarter, both due to a mix of higher prices and increased volume. Net earnings fell 12% in 4Q13 as a result of lower operating income and a higher effective tax rate.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus